Review highlights management strategies and pathogenesis of high-altitude pulmonary hypertension, suggesting effective interventions.
High-altitude pulmonary hypertension (HAPH) is a life-threatening disorder caused by hypobaric hypoxia at high altitudes. This review summarizes the latest advances in the pathogenesis and management of HAPH. The pathogenesis mainly involves hypobaric hypoxia, persistent pulmonary arteriolar constriction, smooth muscle cell proliferation, and vascular remodeling. Current therapeutic strategies include pharmacotherapy (PDE-5 inhibitors, endothelin receptor antagonists, prostacyclins, traditional Chinese medicine, and Tibetan medicine), oxygen therapy, and surgical interventions such as pulmonary arterial denervation and transplantation. This paper aims to provide updated evidence and clinical insights for the prevention and treatment of HAPH in high-altitude residents and travelers.
No takes yet. Share an insight, caveat, or question.
Hua et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: